ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SBFM vs JNJ // EV/EBITDA & P/E VALUATION

Sunshine Biopharma Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: SBFM 0 — JNJ 9
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SBFM VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SBFM JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 33.80% 67.90% -34.10 JNJ /gross-margins <GO>
Return on Invested Capital (ROIC) -21.40% 25.50% -46.90 JNJ /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield — 2.97% — TIE /fcf-yield <GO>
Operating Margin -17.20% 34.70% -51.90 JNJ /operating-margins <GO>
Net Profit Margin -16.50% 28.50% -45.00 JNJ /net-margins <GO>
Revenue Growth (YoY) 4.10% 6.00% -1.90 JNJ /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 5.59 -5.39 JNJ /balance-sheet <GO>
Piotroski F-Score Quality 4/9 8/9 -4.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 27.3 62.1 -34.77 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.5M $662.49B -$662.49B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SBFM REV JNJ REV SBFM GROSS % JNJ GROSS % SBFM FCF JNJ FCF
FY 2025 $36.3M $94.19B 33.8% 67.9% -$5.5M $19.70B
FY 2024 $34.9M $88.82B 30.6% 69.1% -$14.2M $19.84B
FY 2023 $24.1M $85.16B — — -$8.8M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SBFM // BETA —
JNJ // BETA 1.08